A phase I, dose finding, pharmacokinetic, and safety study of continuous IV [intravenous] infusion of ECO-4601 [TLN 4601] in patients with advanced cancer including an extension portion to obtain safety data at the highest tolerable dose.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diazepinomicin (Primary)
Indications Breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors BELLUS Health

Most Recent Events

10 Jul 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
22 Aug 2007 Status changed from recruiting to in progress.
01 Jun 2007 Interim results have been reported

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight